GERHARD CARL HILDEBRANDT

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology COLUMBIA, MO NPI 1245568633

General Payments — all program years on this page

$50,356.44

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 103
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $8,582.27 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $6,891.252
Food and Beverage $846.0812
Travel and Lodging $844.945

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Incyte Corporation $5,646.498
Genmab U.S., Inc. $2,425.065
JAZZ PHARMACEUTICALS INC. $273.292
BeiGene USA, Inc. $113.401
Rigel Pharmaceuticals, Inc. $84.181
PFIZER INC. $20.441
Kite Pharma, Inc. $19.411

By program year

Program yearAmountRecords
2018 $15,158.5729
2019 $9,265.0821
2020 $5,461.546
2021 $3,142.502
2022 $2,536.217
2023 $6,210.2719
2024 $8,582.2719

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1120856426 BeiGene USA, Inc. $113.40 04/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126826748 Genmab U.S., Inc. $2,096.25 07/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1126826750 Genmab U.S., Inc. $171.52 07/26/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1126826752 Genmab U.S., Inc. $25.00 07/26/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1126826754 Genmab U.S., Inc. $130.00 07/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126826756 Genmab U.S., Inc. $2.29 07/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1128612269 Kite Pharma, Inc. $19.41 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131301461 PFIZER INC. $20.44 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141169337 Incyte Corporation $50.00 11/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141170317 Incyte Corporation $50.00 11/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141233409 Incyte Corporation $13.40 11/09/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1141267631 Incyte Corporation $261.06 11/09/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1141293026 Incyte Corporation $73.07 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141308323 Incyte Corporation $4,795.00 11/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141308327 Incyte Corporation $30.00 11/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141315525 Incyte Corporation $373.96 11/08/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1145207819 Rigel Pharmaceuticals, Inc. $84.18 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150206044 JAZZ PHARMACEUTICALS INC. $129.86 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150206046 JAZZ PHARMACEUTICALS INC. $143.43 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.